Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxypertine SCHEMBL31153315 | 1.00 | DRD2 (1.00) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL1515 | 1.00 | DRD2 (1.00) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL3440995 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL3478579 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL5069690 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL20270862 | 0.99 | DRD2 (0.98) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL21268763 | 0.97 | HTR1A (0.94) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL2837214 | 0.97 | DRD2 (0.94) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| Oxypertine SCHEMBL7527152 | 0.94 | HTR1A (0.88) | DRD2HTR1ANR1I2ADRB1ADRA2A | |
| SCHEMBL2615395 | 0.92 | DRD2 (0.84) | DRD2HTR1ANR1I2ADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | CHANGCHUN HUAPU BIOTECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-06-30 | — | — | US | disclosed |
| EP-4017595-A1 | TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST | Pandion Operations, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114191619-A | Preparation method of injectable porous microspheres with micro/nano composite topological structure | 苏州大学附属第一医院 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021034890-A1 | TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST | Pandion Therapeutics, Inc. (US) | 2021-02-25 | — | — | WO | disclosed |
| CN-111635462-A | Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof | 江苏靶标生物医药研究所有限公司 | 2020-09-08 | — | — | CN | disclosed |
| CN-111607005-A | Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof | 江苏靶标生物医药研究所有限公司 | 2020-09-01 | — | — | CN | disclosed |
| CN-111592601-A | Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof | 江苏靶标生物医药研究所有限公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111548425-A | Tumor targeting tumor necrosis factor related apoptosis ligand variant and application thereof | 江苏靶标生物医药研究所有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-110215517-A | The application of signal path signal inhibitor or protein synthesis inhibitor or madecassoside on preparation treatment medicine for treating osteoporosis | 温州医科大学 | 2019-09-10 | — | — | CN | disclosed |
| WO-2009088250-A2 | POROUS HOLLOW SILICA N ANOP ARTICLES, PREPARATION METHOD OF THE SILICA NANOPARTICLES, AND DRUG CARRIERS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SILICA NANOPARTICLES | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2009-07-16 | — | — | WO | disclosed |
| EP-1589996-A4 | ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULAT IONS AND USES THEREOF | MEDIMMUNE INC (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008020666-A1 | EMBRYONIC STEM CELL-LIKE CELLS | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008020657-A1 | ACQUIRED PLURIPOTENCY THROUGH OVARIAN NICHE | SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) | 2008-02-21 | — | — | WO | disclosed |
| WO-2005117976-A2 | METHOD OF INCREASING RADIATION SENSITIVITY BY INHIBITION OF BETA ONE INTEGRIN | THE REGENT OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-15 | — | — | WO | disclosed |
| EP-1589996-A2 | ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULAT IONS AND USES THEREOF | MEDIMMUNE, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2005037194-A2 | COLLAGEN INTERACTIONS WITH PROSTATE CANCER CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004066957-A2 | ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF | MEDIMMUNE, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003059872-A1 | AVB3 AND AVB5 INTEGRIN ANTAGONISTS AND METHODS OF TREATING DISEASES OR CONDITIONS ASSOCIATED WITH AVB3 AND AVB5 INTEGRINS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2002100325-A2 | POLYVALENT NANOPARTICLES | LIGOCYTE PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203504-A1 | IMMUNOMODULATORY POLYNUCLEOTIDES AND USES THEREOF | TLR3, TLR9, CD47 | DRD2 4868/4885HTR1A 4760/4885NR1I2 4297/4885 |
| US-20220204641-A1 | ANTI-CD20 COMBINATIONS FOR TREATING TUMORS | CD209, CD68, CD47 | DRD2 2478/4885HTR1A 4055/4885NR1I2 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.